11/19/2026 | Press release | Distributed by Public on 11/19/2026 10:55
Today's big story: Could Anthropic Stock Fall 25%?
Boston Scientific (BSX) stock trades at 18.1 times earnings, against 21.5 for the S&P 500. That price comes after the shares fell 57.1% over the past twelve months, while the S&P 500 gained 11.0%. Anyone buying at this price needs to know what they are buying. The company's priorities have changed. A year ago, management talked up the growth of its WATCHMAN implant. Now it emphasizes something else. So what does management talk up now?
Anyone who bought Boston Scientific a year ago has lost 57.1%, more than half the money. If the stock is a big part of your savings, that is a deep hole to sit through while management works to restart growth. When the market has fallen, the Trefis High Quality (HQ) Portfolio has lost about 81 cents for every $1 its benchmark lost, on average. See the HQ record.
What Boston Scientific Talks Up Now
Management now makes the case for the rest of the company. Boston Scientific held its fiscal Q3 2026 call on October 28, 2026. On it, management said two businesses are now holding back the company's growth. They are WATCHMAN and EP, the unit that treats irregular heartbeats with its FARAPULSE platform. Management said the rest of the company accounts for 75% of the business and is growing steadily. So the pitch has moved away from the two products that once led the growth.
A year earlier, the message was different. On the fiscal Q3 2025 call, management said WATCHMAN "grew an outstanding 35% this quarter." Back then, WATCHMAN was part of a fast-growing company. Organic sales grew 15% that quarter, coming in above the high end of management's guidance.
How Are Both Parts Of Boston Scientific Doing?
WATCHMAN and EP are now weighing on growth. In fiscal Q3 2026, WATCHMAN sales fell 7% in the U.S. from a year earlier. EP sales fell 5% worldwide. EP sales fell 5% from a year earlier. Management said EP's strong market share position has eroded as new technologies arrive.
Parts of the other 75% are growing fast. The interventional cardiology business grew 19% in fiscal Q3 2026. Not every part kept up, though. Urology sales declined 3%, hit in part by the cyber incident the company suffered in the quarter. The incident caused a two-week outage, and operations were back up by September 8.
Put together, Boston Scientific barely grew. Organic sales rose 1.5% in fiscal Q3 2026, against organic growth of 15% in fiscal Q3 2025. Management estimates the cyber incident cut growth by about 3 percentage points. Even without that hit, growth would have been far below the pace of a year ago.
What Does Boston Scientific's New Focus Mean For You?
For now, the new focus is more concerning than reassuring. Management says it will be challenged to grow sales and adjusted earnings per share in 2027, leaving aside its pending purchase of Penumbra. It now expects that deal to close in early 2027, subject to the remaining regulatory clearances. It believes 2027 will be the trough for WATCHMAN and EP. It aims to return to high performance in 2028, but that is a goal, not a result. Even that goal is modest: management said 2028 growth could be solid but still below the roughly 7% growth rate of its markets. It expects to beat that rate in 2029.
Boston Scientific trades below the S&P 500's earnings multiple. Yet by management's own account, it may struggle to grow in 2027, leaving aside the Penumbra purchase. The growing part of the business is real, but it has not yet been enough to carry the whole company. Boston Scientific is expected to report next in February 2027. That report will show how WATCHMAN and EP sales compare with a year earlier.
A year ago, Boston Scientific's growth looked as steady as a holder could want, and it turned within a few quarters. Building wealth is easier when no single stock's reversal can cost you your peace of mind.
What If You Could Grow Wealth And Still Sleep At Night?
Boston Scientific is 57% below its highest close of the past year. How has that felt? The Trefis Income Solution pays a dividend yield about 3x the S&P 500's, and it lost less than the S&P 500 in all 9 big selloffs since 2018.
Spot an error or want more like this? Tell us in 10 seconds.